Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase Ib/II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

NCT07136181 is registered in ClinicalTrials.gov with Novelwise Pharmaceutical Corporation as lead sponsor.

NCT NCT07136181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07136181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase Ib/II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
Lead sponsor
Novelwise Pharmaceutical Corporation
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 20, 2025
Completion date
August 30, 2029
Enrollment
36 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

eye cancer, eye cancer, intraocular melanoma, metastatic uveal melanoma, uveal melanoma, metastatic, uveal melanoma, recurrent